Kadimastem - Stem Cell to Cure Diseases

News & Events > Press Releases - 2014

Kadimastem Reinforces its Status as a World Leader in the Field of Stem Cells

May. 1, 2014

 

 

Kadimastem Reinforces its Status as a World Leader in the Field of Stem Cells;

Has Added to its Ranks Professor Yosef Itzkowitz-Eldor, an International Leader in the

Stem Cells Field

Professor Itzkowitz-Eldor will join Kadimastem’s Scientific Advisory Board

 

Kadimastem is reinforcing the company’s Scientific Advisory Board. Professor Yosef Itzkowitz-Eldor, amongst the world’s leading experts in the field of stem cell research, is joining Kadimastem as part of the scientific committee which advises the company.

Kadimastem is developing treatment for serious illnesses based on pluripotent stem cells. Prof. Itzkowitz-Eldor is joining a team of international opinion leaders in the field of stem cells who advise and accompany Kadimastem.

This is part of the company’s vision to establish itself as a leading company in the field of pluripotent stem cell research both in Israel and internationally. Prof. Itzkowitz-Eldor’s appointment assists in the realization of this vision, with the company’s Chief Scientist Prof. Michel Revel standing at the head of the Scientific Advisory Board, and with Prof. Benjamin Reubinoff – head of the Obstetrics and Gynecology department at Hadassah, who is also the head of Hadassah’s Human Stem Cell Research Center and one of the world’s pioneers in pluripotent stem cell research – also serving on the committee.

 

Prof. Itzkowitz-Eldor has served as head of the Obstetrics and Gynecology Department at Rambam Medical Center for the last 22 years and is currently a professor in the Technion’s medical school and head of the embryonic stem cell research laboratory. Likewise, Prof. Itzkowitz-Eldor has initiated the collaboration with James Thomson, of the University of Wisconsin in Madison, USA, which has brought about the first production of human embryonic stem cells in the world, and later in Israel.

The research laboratories which he heads study the production of embryonic stem cells of human origin and their differentiation into different types of cells. Prof. Itzkowitz-Eldor has published over 200 scientific papers, in the fields of embryo physiology, fertility medicine, and pluripotent embryonic stem cells.

 

Prof. Michel Revel, Kadimastem’s Chief Scientist, said “We are pleased that Prof. Itzkowitz-Eldor has joined our Scientific Advisory Board. Prof. Itzkowitz-Eldor is a global opinion leader in the field of pluripotent stem cells and was among the first pioneers who successfully created embryonic stem cells. I believe that the proven experience and many accomplishments of Prof. Itzkowitz-Eldor will greatly assist the company’s advancement.”

Yossi Ben-Yosef, the company’s CEO and who founded the company together with Prof. Revel, added “Prof. Itzkowitz-Eldor is joining a team of internationally renowned experts, which places Kadimastem at the forefront of global technology in the field of pluripotent stem cell research and its use to treat serious illnesses.”

About Kadimastem

Kadimastem (www.kadimastem.com) (TASE: KDST) develops human stem cells used to create medical solutions for diabetes and degenerative diseases of the nervous system and to screen drugs. The company’s technological platform makes it possible to differentiate stem cells into a range of functional human cells, including neuron-supporting cells in the brain as well as pancreatic cells that secrete insulin – beta cells.

 

Kadimastem relies on technology that was initially developed at the Weizmann Institute in Prof. Michel Revel’s laboratory, and which are currently developed and advanced in the company’s labs at the Weizmann Science Park. Prof. Revel, who currently serves as the company’s Chief Scientist, is the developer of the Rebif®, the flagship drug of international pharma company Merck Serono for the treatment of Multiple Sclerosis. Kadimastem is developing two types of medical applications: regenerative medicine, whose purpose is to repair and replace tissues and organs that have been damaged by illness using healthy cells grown in a laboratory conditions,  for example, transplantation of insulin-secreting pancreas cells to treat insulin-dependent diabetes, or transplantation of healthy neural cells to support survival of nerve cells and treat ALS.

Likewise, the company has developed a platform for drug screening, which uses functional human cells and tissues to discover new medicines. As of the date of publication, the company has signed a memorandum of understanding regarding a strategic agreement with Merck Serono, intended to broaden the existing commercial cooperation between the two companies for drug screening and discovery for multiple sclerosis and neurodegenerative diseases.


Press Releases Archive